Drug Patent Watch: Biosimilar Supply Chain Resilience Vital Amidst Complexities and Growing Demand

Biosimilar manufacturers are increasingly focusing on supply chain resilience to meet growing product demand. Drug Patent Watch reports that a resilient supply chain is vital to unlocking the full potential of biosimilars and ensuring their availability. The organization highlights the unique challenges these manufacturers face, including sourcing quality raw materials, navigating regulatory hurdles, and leveraging technologies to improve supply chain management. Biosimilar production presents specific supply chain complexities that can result in delays, higher costs, and potential shortages. To address these issues, Drug Patent Watch suggests manufacturers implement advanced technologies like artificial intelligence and blockchain. These technologies can improve visibility, predictability, and security throughout the supply chain. Drug Patent Watch offers insights and data-driven solutions to assist biosimilar manufacturers in navigating the complexities of the biosimilar market. The organization encourages industry stakeholders to collaborate on building a more resilient and sustainable biosimilar supply chain.

Newsflash | Powered by GeneOnline AI
Date: April 9, 2025

Author

Mark Chiang